• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon

2

Current price of oil as of June 8, 2026

3

'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO

1

Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon

2

Current price of oil as of June 8, 2026

3

'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO
TechPharmaceutical Industry
Europe

AstraZeneca to buy cell therapy biotech for up to $1 billion

By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
March 17, 2025, 7:50 AM ET
Pascal Soriot, chief executive officer of AstraZeneca.
Pascal Soriot, chief executive officer of AstraZeneca.Cole Burston/Bloomberg via Getty Images

AstraZeneca Plc, the UK drugmaker, agreed to buy the Belgian cell therapy developer EsoBiotec for as much as $1 billion to further boost its cancer capabilities. 

Recommended Video

AstraZeneca will pay $425 million upfront and may spend up to $575 million more in development and regulatory milestones, the companies said Monday. 

As Chief Executive Officer Pascal Soriot reaps the rewards of doubling down on the competitive market for cancer medicines with blockbusters like Tagrisso, Astra is targeting the next generation of potential treatments. 

EsoBiotec’s platform has the potential to transform cell therapy, according to Astra, by empowering the immune system to attack cancers. It uses targeted viruses to engineer immune cells directly within a person’s body and could allow treatment to be delivered in minutes rather than the current standard of several weeks. 

Astra shares were little changed in early London trading, rising less than 1%. The stock has gained almost 15% so far this year. 

Current CAR-T cell therapies require doctors to harvest cells from patients, engineer them in the laboratory and then re-infuse them into a patient. While these medicines can treat certain cancers, they are expensive and difficult to manufacture, prompting drugmakers to develop medicines that could engineer cells within the body. 

EsoBiotec in January announced the start of a trial testing its experimental therapy for multiple myeloma in collaboration with China’s Shenzhen Pregene Biopharma Co. The goal is to achieve cancer-free bone marrow without requiring chemotherapy to achieve lymphodepletion as needed in traditional CAR-T treatment.

Under the terms of the deal, EsoBiotec will become a subsidiary of Astra and maintain operations in Belgium. The transaction is expected to close in the second quarter. Prior to it, Esobiotec had only raised €22 million ($24 million).

In a separate cancer deal announced Monday, Astra agreed to license a plaform to make subcutaneous drug formulations from Alteogen Inc. It didn’t disclose financial details. 

About the Authors
By Ashleigh Furlong
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Tech

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Tech

Artistic drawing of two employees using several tools at once
AIefficiency
Why dbt Labs CEO views AI efficiency and creativity as the same thing
By Sage LazzaroJune 9, 2026
2 hours ago
Reward or threat? Omnisend offers quarterly raises for employees who use AI to drive business impact—and says those who don’t will get left behind
AIMarketing
Reward or threat? Omnisend offers quarterly raises for employees who use AI to drive business impact—and says those who don’t will get left behind
By Sage LazzaroJune 9, 2026
2 hours ago
Artistic rendering of complex systems being simplified by two workers
AILumen Technologies
How Lumen’s ‘maniacal focus’ on KPIs drove measurable AI impact across use cases and the company at large
By Sage LazzaroJune 9, 2026
2 hours ago
AI agents are flattening corporate hierarchies. Here’s how companies—and managers—can develop a new playbook
AIManagement
AI agents are flattening corporate hierarchies. Here’s how companies—and managers—can develop a new playbook
By Sharon GoldmanJune 9, 2026
2 hours ago
Artistic rendering of a hacker trying to gain access to a worker's computer
AISecurity
AI is supercharging cyberattacks—and most companies aren’t ready
By Beatrice NolanJune 9, 2026
2 hours ago
China builds 85% of the world’s humanoids robots for cheap at scale, but finding buyers is tricky
InnovationRobots
China builds 85% of the world’s humanoids robots for cheap at scale, but finding buyers is tricky
By The Associated Press and Chan Ho-HimJune 9, 2026
2 hours ago

Most Popular

Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon
Environment
Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazon
By Sasha RogelbergJune 8, 2026
19 hours ago
Current price of oil as of June 8, 2026
Personal Finance
Current price of oil as of June 8, 2026
By Joseph HostetlerJune 8, 2026
1 day ago
'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO
Economy
'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPO
By Jim EdwardsJune 8, 2026
1 day ago
Gen Zers are arriving at college unable to even read a sentence—professors warn it could lead to a generation of anxious and lonely graduates
Success
Gen Zers are arriving at college unable to even read a sentence—professors warn it could lead to a generation of anxious and lonely graduates
By Preston ForeJune 7, 2026
2 days ago
'The golden years are not golden': Boomers are hoarding most of America's wealth and power because they're terrified of outliving their money
Economy
'The golden years are not golden': Boomers are hoarding most of America's wealth and power because they're terrified of outliving their money
By Nick LichtenbergJune 7, 2026
2 days ago
Current price of silver as of Monday, June 8, 2026
Personal Finance
Current price of silver as of Monday, June 8, 2026
By Joseph HostetlerJune 8, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.